Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Last trade$10.27
Day change-$0.33 (-3.11%)
Day range$10.19 – $10.92
Volume525,119
Market cap$894M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$894.14M
Price / earnings
—
Price / book
4.29×
Price / sales
—
EV / sales
—
EV / EBITDA
-13.01×
Profitability
Earnings per share
-$0.76
Return on assets
-28.73%
Return on equity
-30.87%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
13.38×
Quick ratio
13.38×
Cash ratio
0.97×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$47.94M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRVS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.58M
$3.33M
$3.7M
$2.28M
$2.12M
$2.39M
$2.47M
$2.13M
Research and development
$17.78M
$15.96M
$11.18M
$9.94M
$8.45M
$7.87M
$7.45M
$5.97M
Total operating expenses
$21.36M
$19.3M
$14.88M
$12.22M
$10.57M
$10.26M
$9.92M
$8.11M
Operating income
-$21.36M
-$19.3M
-$14.88M
-$12.22M
-$10.57M
-$10.26M
-$9.92M
-$8.11M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$20.34M
-$17.96M
-$13.09M
-$13.57M
-$10.16M
-$8M
$15.73M
-$13.14M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$20.34M
-$17.96M
-$13.69M
-$12.32M
-$10.16M
-$8M
$15.19M
-$12.11M
Net income attributable to common shareholders
-$20.34M
-$17.96M
-$13.69M
-$12.32M
-$10.16M
-$8M
$15.19M
-$12.11M
EBITDA
-$21.27M
-$19.26M
-$14.85M
-$12.19M
-$10.54M
-$10.23M
-$9.9M
-$8.09M
Basic earnings per share
-$0.22
-$0.19
-$0.15
-$0.15
-$0.12
-$0.10
$0.21
-$0.18
Diluted earnings per share
-$0.22
-$0.19
-$0.15
-$0.15
-$0.12
-$0.10
-$0.13
-$0.18
Recent news
Company coverage with links to the original publishers.
Corvus Pharmaceuticals director David Scott Moore purchased 21,700 common shares for approximately $250,000 on June 11, 2026, marking his first investment in the company since joining as a director in October. Moore also received 15,000 stock options vesting in a year. The insider buy is viewed as a positive signal, though it should be considered alongside other investment factors.
The peripheral T-cell lymphoma (PTCL) treatment market is projected to grow at a 7% CAGR through 2036, driven by increasing disease incidence and expanding patient populations. The market was valued at USD 800 million in 2025, with the US accounting for 68% of the market. Multiple emerging therapies from major pharmaceutical companies are expected to transform the treatment landscape, with ADCETRIS currently holding the largest market share at over USD 300 million.
Three rapid-growth stocks have significantly outperformed the broader market in early 2026. Corvus Pharmaceuticals surged 188% YTD on positive Phase 1 trial data for its atopic dermatitis drug candidate soquelitinib, with a Phase 2 trial planned for early 2026. New Era Energy & Digital jumped 114% YTD following strategic partnerships in the data center space, though it faces legal scrutiny. USA Rare Earth gained 56% YTD, supported by $1.6 billion in federal investment and strong cash position, though it remains an early-stage firm without proven profitability.
Corvus Pharmaceuticals successfully closed an upsized public offering of 9,085,778 shares at $22.15 per share, generating approximately $201.2 million in gross proceeds. The company plans to use the net proceeds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes.
Corvus Pharmaceuticals priced an upsized underwritten public offering of 7.9 million shares at $22.15 per share, raising approximately $175 million in gross proceeds. The company plans to use the funds for working capital, R&D including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis trials, and general corporate purposes. The offering is expected to close on January 23, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.